Services

IgA-IgG Chimeric Antibody Production Service

Background Service Advantages Applications FAQs

Innovative IgA-IgG Hybrid Antibodies for Enhanced Therapeutic Potency

At Creative Biolabs, we offer a comprehensive IgA-IgG Chimeric Antibody Production Service designed to combine the unique properties of both IgA and IgG antibodies. This hybrid format is engineered to enhance both immune effector functions and pharmacokinetic properties. Our service aims to optimize the potential of chimeric antibodies, merging IgA's mucosal targeting capabilities with IgG's serum half-life extension.

With expertise in antibody engineering, we provide end-to-end solutions—from custom chimeric antibody design to recombinant production, purification, and functional validation. We ensure that every chimeric antibody meets the specific requirements for your therapeutic programs.

Service Highlights

Custom Chimeric Antibody Design

Hybrid formats: Design IgA Fab and IgG Fc combinations (IgA1, IgA2, IgG1, IgG4) to optimize therapeutic performance.
Flexibility: Tailor the linker regions for structural stability and optimal receptor engagement.
FcRn binding: Engineer the Fc region to incorporate FcRn-binding motifs, ensuring improved serum half-life.

Functional Assays

FcαRI binding for IgA-specific effector function.
FcγRI/III activation for IgG-mediated immune responses.
FcRn binding assays at acidic (pH 6.0) and neutral (pH 7.4) pH to confirm serum half-life extension.
ADCC and phagocytosis assays for evaluating immune cell recruitment and activation.

Purification & Quality Control

Utilize affinity chromatography (Protein A/G/L) for high-purity antibody isolation.
Full analytical characterization including SDS-PAGE, SEC-HPLC, mass spectrometry, and glycosylation profiling.

Recombinant Expression

CHO or HEK293 expression systems for high-yield, glycosylation-optimized antibody production.

Advantages of Our Service

Dual Immune Engagement: Combine IgA's mucosal immunity with IgG's systemic bioavailability, enabling both local and systemic immune responses.
Optimized Half-Life: Through engineered FcRn binding, our IgA-IgG chimeric antibodies are designed for prolonged circulation, reducing the need for frequent dosing.
Comprehensive Testing: Full suite of functional assays ensures that your chimeric antibody meets the desired potency and therapeutic profile.

Applications

Fig.1 Applications of this service. (Creative Biolabs Original)

FAQs

Q1: What makes IgA-IgG chimeric antibodies special?

A1: These antibodies combine IgA's mucosal immunity with IgG's longer serum half-life, offering dual functionality to target both local and systemic disease.

Q2: How does the FcRn binding motif work?

A2: The FcRn binding motif in the IgG Fc region facilitates recycling in the bloodstream, thus prolonging the half-life of the antibody.

Q3: How do you validate the functional activity of chimeric antibodies?

A3: We perform Fc receptor binding assays, ADCC, and phagocytosis assays, as well as FcRn binding tests to ensure your antibody's efficacy.

Contact Us

At Creative Biolabs, we specialize in the development and production of IgA-IgG chimeric antibodies, tailored to meet the unique needs of your therapeutic or research applications. Whether you are looking to optimize bispecific antibody formats, enhance immune effector function, or explore long-acting therapeutics, our team is here to support your goals.

If you would like to learn more about our IgA-IgG Chimeric Antibody Production Service or discuss your specific project needs, please reach out to us.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.